The evolving landscape of chimeric antigen receptor T-cell therapy associated cardiotoxicity

Part of the inconsistency in reporting cardiac adverse events in these CAR T-cell therapy studies is that some of the authors considered the combination of tachycardia and hypotension requiring use of vasopressors a cardiac event, whereas others did not. Most recently, using the U.S. Food and Drug Administration Adverse Event Reporting System, Goldman and colleagues [10] found that CAR T-cell therapy was associated with overreporting of tachyarrhythmia, cardiomyopathy, and pericardial disease. For this reason, until more robust data are available with full characterization of a cardiotoxic profile as well as development of a standardized grading guideline for cardiotoxicity, considering CAR T-cell therapy-associated cardiotoxicity in this subset of patients in the emergency department is important.Disclosures None.Funding None.Declaration of Competing Interest None.Acknowledgement The authors would like to thank Don Norwood from the Research Medical Library at The University of Texas MD Anderson Cancer Center for editing this article.